



## Clinical Study Synopsis for Public Disclosure

This clinical study synopsis is provided in line with **Boehringer Ingelheim's Policy on Transparency and Publication of Clinical Study Data**.

The synopsis - which is part of the clinical study report - had been prepared in accordance with best practice and applicable legal and regulatory requirements at the time of study completion.

The synopsis may include approved and non-approved uses, doses, formulations, treatment regimens and/or age groups; it has not necessarily been submitted to regulatory authorities.

A synopsis is not intended to provide a comprehensive analysis of all data currently available regarding a particular drug. More current information regarding a drug is available in the approved labeling information which may vary from country to country..

Additional information on this study and the drug concerned may be provided upon request based on **Boehringer Ingelheim's Policy on Transparency and Publication of Clinical Study Data**.

The synopsis is supplied for informational purposes only in the interests of scientific disclosure. It must not be used for any commercial purposes and must not be distributed, published, modified, reused, posted in any way, or used for any other purpose without the express written permission of Boehringer Ingelheim.

<b>Name of Company:</b> Boehringer Ingelheim		<b>Statement on discontinuation of the study</b>	 <b>Boehringer Ingelheim</b>
<b>BI Proprietary Name:</b> NA		<b>EudraCT No.:</b> 2015-001477-41	
<b>BI Investigational Product:</b> BI 1361849		<b>Page:</b> 1	
<b>Report Date:</b> NA	<b>Trial No. / Doc. No.:</b> 1373.1	<b>Dates of Trial:</b> NA	<b>Date of Revision:</b> NA
<b>Proprietary confidential information</b> © 2018 <b>Boehringer Ingelheim International GmbH</b> or one or more of its affiliated companies. All rights reserved. This document may not - in full or in part - be passed on, reproduced, published or otherwise used without prior written permission			
<b>Title of Trial:</b>	A randomised, double blind phase I/II trial to investigate efficacy, immunogenicity and safety of intradermally administered BI 1361849 (CV9202) plus afatinib versus placebo plus afatinib as first-line treatment for patients with stage IV adenocarcinoma of the lung harbouring common EGFR mutations		
<b>Trial Sites:</b>	NA		
<b>Publications:</b>	NA		
<b>Clinical Phase:</b>	I/II		
<b>Statement on discontinuation of the study:</b>	Discontinued by <b>Boehringer Ingelheim</b> during preparing of the trial. No patients entered the study, therefore no results / data are available.		